Long-term therapy to prevent stroke.
Cerebrovascular disease is the third leading cause of mortality and the leading cause of long-term neurological disability in the United States. Most strokes are of ischemic origin and, other than cardioembolic or small vessel strokes, are caused by the development of platelet-fibrin thrombi on an atherosclerotic plaque. This underlying disease mechanism shares important features with coronary artery disease and peripheral artery disease, highlighting the systemic nature of atherothrombosis and the elevated cross risk in stroke patients for ischemic events in other vascular beds. It has been estimated that up to 80% of ischemic strokes could be prevented with application of currently available treatments for blood pressure, cholesterol, and antithrombotic therapies. Stroke is not, like cancer, waiting for a scientific breakthrough; stroke preventive treatments are well understood and widely available. It is only the application of these treatments to patients, many of whom do not visit physicians, that is lacking. Clearly, better education of the public and active participation of primary care physicians is essential to get the message out to all those at risk.
Kirshner
Howard S
HS
Department of Neurology, Vanderbilt University Medical Center, 2100 Pierce Avenue, Nashville, TN 37212, USA. Howard.Kirshner@vanderbilt.edu
Biller
José
J
Callahan
Alfred S
AS
D000925:Anticoagulants / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002339:Carotid Arteries / Q000601:surgery; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008134:Long-Term Care / Q000379:methods; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011315:Preventive Medicine / Q000379:methods*; D012307:Risk Factors; D020521:Stroke / Q000503:physiopathology / Q000517:prevention & control*; D014481:United States
D000925:Anticoagulants; D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors